key: cord-0928618-62lgfxj4 authors: Lawrensia, Sherly; Henrina, Joshua; Cahyadi, Alius title: Multisystem inflammatory syndrome in adults: a systematic review and meta-analysis of the rheumatological spectrum of complications post COVID-19 infection date: 2021-09-28 journal: Revista Colombiana de Reumatología DOI: 10.1016/j.rcreu.2021.09.002 sha: 1b56a7f637ee6eb6f57a54c2c09ee6cedd74a846 doc_id: 928618 cord_uid: 62lgfxj4 Multisystem inflammatory syndrome in adults (MIS-A) is a rare but severe complication in adults infected with SARS-CoV-2. However, the pathophysiology remains elusive, as the limited number of reports preclude a broader understanding of this syndrome. We conducted this systematic review to explore the clinical spectrum of MIS-A, in particular its rheumatological manifestations. Meta-analyses of case-series were also performed. We identified 28 patients from 14 case reports and two case series of MIS-A. This disease occurred equally in both genders, with a mean age of 33+10 years old, and predominantly in those of African descent (40%). Rheumatological manifestations consisted of Kawasaki Disease (KD)-like symptoms. Ninety percent of patients had positive COVID-19 serology tests, while 48% of patients were negative for COVID-19 RT-PCR test. Twelve patients were admitted to ICU and unfortunately two died. Although the signs and symptoms of MIS mimicked KD, the gastro-intestinal findings were more prominent in the former group. The demographic make-up was also different, with MIS-A occurring mostly in those of African descent. Importantly, unlike their paediatric counterparts, the adult group did not have coronary artery abnormalities. Long-term monitoring is needed as safety data is scarce. Of note, although the prognosis of MIS-A is excellent, the life-threatening nature of this syndrome demands intensive care unit level of care and mechanical support. During the COVID-19 pandemic, a constellation of KD symptoms in an adult patient should alert the clinician to the possibility of MIS-A. Since the emergence of coronavirus disease of 2019 (COVID-19) from Wuhan, China on December 31, 2019, this disease has become the deadliest pandemic in modern human history, with mortality worldwide has soared to more than two million people and affecting more than 100 million people. 1 At first, in the early pandemic, this disease was thought to be innocuous in the pediatric population. 2 Then, on April Page 4 of 25 J o u r n a l P r e -p r o o f 4 7, 2020, it was found that COVID-19 was associated with life-threatening postinfectious disease in pediatric populations identified as pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C). 3 Later, in June 2020, it was also identified to occur in the adult population known as MIS-A. 4 Nevertheless, the pathophysiology remains elusive, as a limited number of reports preclude a broader understanding of this syndrome. Therefore, we conducted this systematic review to explore the clinical spectrum of MIS-A, precisely its rheumatological manifestations. Subsequently, we hoped that this finding would fill in, in part, the knowledge gap, and help us with generating hypotheses. Moreover, this article was previously presented as a meeting abstract at the "Reumatologi Klinik Bandung 2021" event on February 14, 2021. We performed a systematic review of the literature consisting of case reports and case series following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 5 "SARS-CoV-2" AND "rheumatic" OR "vasculitis" OR "arthritis" OR "rheumatoid" OR "autoimmune" OR "rash". We finalized the search on 29 January 2021. The inclusion criteria were case reports or case series that reported clinical manifestations or characteristics of patients meeting the criteria of MIS-A. 4 We exclude non-English articles, articles without pertinent data, and articles without fulltext availability. Two independent reviewers (SL and JH) screened the titles and abstracts for full-text eligibility and applied protocol inclusion and exclusion criteria to the full-text publication. Any discrepancies were discussed with third reviewers (AC). The study selection flowchart were shown in Figure 1 . We collected the data regarding the first author name, country, study type, (Table. S3) Each study was assessed for their risk of bias according to their type of studies. Each tool for case report and case series were consisted of eight and ten questions, respectively. Subsequently, overall evaluation of the bias assessment risk was interpreted with low risk of bias, high risk of bias, or unclear. Studies with suspected high risk of bias were excluded. In total, we identified 28 patients from sixteen studies consisting of fourteen case reports and two case series that reported clinical manifestations of MIS-A. 4,6,7-1415-20 All of the extracted variables and risk of bias analysis are in the supplementary file. Of 28 patients with MIS-A, 14 (50%) were male. The mean age (SD) of patients with MIS-A was 33 (10) years. Of twelve studies that reported data on ethnicity (n=20), 7 eleven (55%) were African, five (25%) were Latin or Hispanic, three (15%) were African, one (5%) was Pakistan, one (5%) was American, one (5%) was Caucasian, and one (5%) was Asian. [4, 6, 20, 21, [8] [9] [10] 12, 13, [17] [18] [19] The mean (SD) of BMI was 28.58 (5.6) kg/m2. [6, 9, [12] [13] [14] 17, 19 ] Of 22 patients from ten studies, nine patients (40.9%) did not have any comorbidity, six (27.3%) were obese, four (18.2%) had hypertension, three (13.6%) had diabetes, two (9.1%) had blood disorder (sickle cell disease and thalassemia major), and one (4.5%) had asthma. 4, 6, [7] [8] [9] [12] [13] [14] 18, 19, 20 Table 1 depicts the demographic characteristic of patients with MIS-A in this study. Table 2 . Table 4 . Of 20 patients, 12 (60%) were admitted to ICU. Unfortunately, of 22 patients hospitalized, two patients died (1.1%). The mean length of stay among 19 patients was 11 (6) days. The forest plot shows the baseline characteristics, clinical findings, treatment, and outcome related to MIS-A. (Figure 2 ) A hyperinflammation syndrome that manifests late in the course of SARS-CoV-2 infection was firstly reported in children and has become an identifiable syndrome. This condition was subsequently known as a multisystem inflammatory syndrome in children (MIS-C). 22 Nevertheless, although initially it was only reported in children patients under 21 years of age, ever since June 2020, there were some case reports with similar conditions that occurred in adults, which was then called multisystem inflammatory syndrome in adults (MIS-A). 4 However, interim guidance for MIS-A has not been elucidated yet since the clinical guidance released by the American College of Rheumatology was only limited to children. 23 In this study, we identified sixteen studies consisting of fourteen case reports and two case series. In our study, the mean age (SD) was 33 (10) years old. Some studies reported cases of young adults who met the MIS-A criteria except for the age category were excluded from this study. Several ethnicities reported from this study Kawasaki disease was initially thought to be generally rare in adults. Nevertheless, patients with MIS-A were reported for having KD-like symptoms. We found that although MIS's signs and symptoms mimicked KD, the gastrointestinal findings were more prominent in the former group. Importantly, unlike the pediatric counterparts, the adult group rarely experiences coronary artery abnormalities. 14 Adults were more prone to experience myocarditis, which was proven by cardiac As COVID-19 vaccine rollout is increasing throughout the world, clinicians should be cognizant of MIS-A's clinical spectrum because this syndrome is theoretically a potential side effect of COVID-19 vaccination that cannot be confidently ruled out, especially for vaccines which mechanism of action rely on stimulating B lymphocytes. Moreover, the post-vaccination antibody titer that will rise or increase after two doses of injection will obscure MIS-A patients' identification. Nonetheless, regardless of this possibility, the benefit of COVID-19 vaccination will likely transcend its harm. rheumatologist at the forefront and lead the patient care, considering other autoimmune diseases that resemble this novel syndrome, such as the macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH) 18 and Kawasaki disease, as well as their experience on immunomodulators and immunosuppressants. There were several limitations of this study. First, we could not rule out the possibility of selection bias, i.e., whether all cases or only a few selected individuals are described. In addition, we could not rule out ascertainment bias as we could not ensure whether all case reports or case series are self-reported or through clinical records or administrative codes, in which the latter are more reliable than the earlier. Finally, reliable conclusions could not be drawn, and more prospective observational cohort studies are needed. Nevertheless, our systematic review and meta-analysis compiles 16 studies, which will help with the rapid dissemination of these important findings. Further reports or studies related to the hyperinflammatory reaction among MIS-A patients are still needed to better elucidate its immunopathology and define the best treatment approach. Rheumatologic spectrum of MIS-A mimics all typical signs of Kawasaki disease, with gastrointestinal and cardiovascular perturbations more prominent in the former than the latter. Therefore, amidst the COVID-19 pandemic, a constellation of KD symptoms in an adult patient should alert the clinician of the possibility of MIS-A. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus Disease Guidance: RC of P and CH. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 Multisystem inflammatory syndrome in children and adolescents temporally related to COVID Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection -United Kingdom and United States Guidelines and guidance preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement A Case of multisystem inflammatory syndrome post-COVID-19 infection in an adult A young adult with COVID-19 and multisystem inflammatory syndrome in children (MIS-C)-like illness: a case report Adult inflammatory multi-system syndrome mimicking kawasaki disease in a patient with COVID-19 Adult post COVID-19 multisystem inflammatory syndrome and thrombotic microangiopathy Team =UCLH COVID response. An adult presentation consistent with PIMS-TS An adult with COVID-19 Kawasaki-like syndrome and ocular manifestations An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19 Vander Heide RS. Cardiac endotheliitis and multisystem inflammatory syndrome after COVID-19 Coronavirus disease 2019 acute myocarditis and multisystem inflammatory syndrome in adult intensive and cardiac care units Coronavirus disease 2019-related Kawasaki-like disease in an adult: A case report COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult Multisystem inflammatory syndrome with complete Kawasaki disease features associated with SARS-CoV-2 infection in a young adult. A case report O01 Adult onset PIMS-TS with secondary haemophagocytic lymphistiocytosis: into the eye of the cytokine storm Case 24-2020: a 44-year-old woman with chest pain, dyspnea, and shock Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives -a report of the European Academy of Allergy and Clinical Immunology (EAACI) Multisystem inflammatory syndrome in children and Kawasaki disease: two different illnesses with overlapping clinical features Clinical Guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19 Multisystem inflammatory syndrome in adults: coming into focus Striking similarities of multisystem inflammatory syndrome in children and a myocarditis-like syndrome in adults: overlapping manifestations of COVID-19 Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children None.